Role of 2,3-Dichloro-6-(trifluoromethoxy) Quinoxaline in Combating Candida Infections
Journal of Pure and Applied Microbiology · 01.12.2025 · 19 (4) · 3106-3115
DOI: 10.22207/jpam.19.4.52 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pure and Applied Microbiology, online erschienen am 08.12.2025. Verfasst von Hatoon A. Niyazi und 18 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The increasing prevalence of Candida infections is a major healthcare challenge, underscoring the need for novel therapeutic agents. In this study, we evaluated the antifungal and anti-inflammatory activity of 2,3-dichloro-6-(trifluoromethoxy) quinoxaline against various Candida and Aspergillus species using both in vitro and in vivo models. Using the broth microdilution method, 21 reference strains were evaluated, revealing notable fungicidal activity particularly against Candida glabrata and Candida krusei, while variable susceptibility was observed in C. albicans, C. tropicalis, and C. parapsilosis. However, no activity was detected against Aspergillus species. In the oral candidiasis mice model, significant antifungal efficacy was confirmed against C. albicans. Moreover, 2,3-dichloro-6-(trifluoromethoxy) quinoxaline exhibited pronounced anti-inflammatory effects, as evidenced by a dose-dependent reduction in pro-inflammatory markers such as IL-6, IL-1β, COX-2, iNOS, and IFN-γ (p < 0.05 at concentrations of 0.02 and 0.2 mg/mL). Taken together, these findings indicate that 2,3-dichloro-6-(trifluoromethoxy) quinoxaline has dual antifungal and anti-inflammatory potential, positioning it as a promising candidate for further preclinical development.
Zitieren
APA
Niyazi, H. A., Niyazi, H. A., Helmi, N. R., Juma, N. A., Saleh, B. H., Alqarni, M. A., Mokhtar, J. A., Attallah, D., Alkuwaity, K., Sait, A. M., Taha, S. E., Ismail, M. A., Alharbi, O. S., Halabi, W. S., Alharbi, M. T., Altalhi, R., Elfadil, A., Ibrahem, K., & Alhazmi, W. (2025). Role of 2,3-Dichloro-6-(trifluoromethoxy) Quinoxaline in Combating Candida Infections. Journal of Pure and Applied Microbiology, 19(4), 3106-3115. https://doi.org/10.22207/jpam.19.4.52
Vancouver
Niyazi HA, Niyazi HA, Helmi NR, Juma NA, Saleh BH, Alqarni MA, et al. Role of 2,3-Dichloro-6-(trifluoromethoxy) Quinoxaline in Combating Candida Infections. Journal of Pure and Applied Microbiology. 2025;19(4):3106-3115. doi:10.22207/jpam.19.4.52
BibTeX
@article{Niyazi2025,
author = {Niyazi, Hatoon A. and Niyazi, Hanouf A. and Helmi, Noof R. and Juma, Noha A. and Saleh, Bandar H. and Alqarni, Mona A. and Mokhtar, Jawahir A. and Attallah, Dalya and Alkuwaity, Khalil and Sait, Ahmad M. and Taha, Sahar E. and Ismail, Mazen A. and Alharbi, Ohood S and Halabi, Waiel S. and Alharbi, Mohanned T. and Altalhi, Rawan and Elfadil, Abdelbagi and Ibrahem, Karem and Alhazmi, Wafaa},
title = {Role of 2,3-Dichloro-6-(trifluoromethoxy) Quinoxaline in Combating Candida Infections},
journal = {Journal of Pure and Applied Microbiology},
year = {2025},
volume = {19},
number = {4},
pages = {3106--3115},
doi = {10.22207/jpam.19.4.52}
}
EUVIMED